PL4051708T3 - Formulacje suchego proszku przeciwciał wiążących limfopoetynę zrębu grasicy (tslp) i sposoby ich zastosowania - Google Patents

Formulacje suchego proszku przeciwciał wiążących limfopoetynę zrębu grasicy (tslp) i sposoby ich zastosowania

Info

Publication number
PL4051708T3
PL4051708T3 PL20797753.9T PL20797753T PL4051708T3 PL 4051708 T3 PL4051708 T3 PL 4051708T3 PL 20797753 T PL20797753 T PL 20797753T PL 4051708 T3 PL4051708 T3 PL 4051708T3
Authority
PL
Poland
Prior art keywords
tslp
methods
dry powder
binding antibodies
powder formulations
Prior art date
Application number
PL20797753.9T
Other languages
English (en)
Inventor
Catherine Eugenie Chaillan Huntington
Susan Hoe
Prakash MANIKWAR
Roland Wilhelm Kolbeck
Emma Suzanne Cohen
Saba Ghazvini
David Lechuga-Ballesteros
Kellisa Beth Hansen
Dexter Joseph D'sa
Original Assignee
Medimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Limited filed Critical Medimmune Limited
Publication of PL4051708T3 publication Critical patent/PL4051708T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
PL20797753.9T 2019-10-28 2020-10-27 Formulacje suchego proszku przeciwciał wiążących limfopoetynę zrębu grasicy (tslp) i sposoby ich zastosowania PL4051708T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962926833P 2019-10-28 2019-10-28
PCT/EP2020/080201 WO2021083908A1 (en) 2019-10-28 2020-10-27 Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
PL4051708T3 true PL4051708T3 (pl) 2025-04-28

Family

ID=73030137

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20797753.9T PL4051708T3 (pl) 2019-10-28 2020-10-27 Formulacje suchego proszku przeciwciał wiążących limfopoetynę zrębu grasicy (tslp) i sposoby ich zastosowania

Country Status (31)

Country Link
US (3) US11904053B2 (pl)
EP (1) EP4051708B1 (pl)
JP (3) JP7680654B2 (pl)
KR (1) KR20220088752A (pl)
CN (1) CN114867748A (pl)
AR (1) AR120309A1 (pl)
AU (1) AU2020376222A1 (pl)
CA (1) CA3154999A1 (pl)
CL (1) CL2023003432A1 (pl)
CO (1) CO2022005391A2 (pl)
CR (1) CR20220189A (pl)
DK (1) DK4051708T3 (pl)
ES (1) ES3017790T3 (pl)
FI (1) FI4051708T3 (pl)
HR (1) HRP20250300T1 (pl)
HU (1) HUE071069T2 (pl)
IL (1) IL292437A (pl)
LT (1) LT4051708T (pl)
MA (1) MA57519B1 (pl)
MX (1) MX2022005083A (pl)
MY (1) MY210226A (pl)
PH (1) PH12022551022A1 (pl)
PL (1) PL4051708T3 (pl)
PT (1) PT4051708T (pl)
RS (1) RS66646B1 (pl)
SI (1) SI4051708T1 (pl)
SM (1) SMT202500220T1 (pl)
TW (1) TWI891670B (pl)
UA (1) UA129038C2 (pl)
WO (1) WO2021083908A1 (pl)
ZA (1) ZA202205936B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20230533A (es) * 2021-04-19 2024-04-05 Medimmune Ltd Un fab anti-tslp con estabilidad mejorada
WO2023064770A1 (en) * 2021-10-11 2023-04-20 Board Of Regents, The University Of Texas System Dry formulations of anti-sars-cov-2 virus antibodies and compositions and methods of use thereof
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
TW202529811A (zh) 2024-01-29 2025-08-01 瑞典商阿斯特捷利康公司 胸腺基質淋巴細胞生成素（ｔｓｌｐ）結合片段之組成物及其使用方法
WO2025242605A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
DE69430824T2 (de) 1993-08-12 2003-01-23 Neurotech S.A., Evry Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
US7259247B1 (en) 1997-09-23 2007-08-21 Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes Anti-human T-cell costimulating polypeptide monoclonal antibodies
PT1149114E (pt) 1999-02-03 2014-05-22 Amgen Inc Polipéptidos envolvidos na resposta imunitária
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
PT1218504E (pt) 1999-09-21 2007-10-22 Genetics Inst Llc Novas moléculas gl50 e suas utilizações
EP1666028B1 (en) * 1999-10-29 2010-03-24 Novartis AG Dry powder compositions having improved dispersivity
AU2005254062B2 (en) * 2002-04-11 2011-02-17 Medimmune, Llc High pressure spray-dry of bioactive materials
SI1915398T1 (sl) 2005-07-18 2016-07-29 Amgen Inc. Humana nevtralizacijska protitelesa proti b7rp1
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
CN102027012A (zh) 2007-06-20 2011-04-20 Irm责任有限公司 用于治疗变应性疾病的方法和组合物
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
JP6077856B2 (ja) 2009-11-04 2017-02-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 操作型抗ｔｓｌｐ抗体本出願は、米国特許仮出願第６１／２９７，００８号（２０１０年１月２１日出願）、および米国特許仮出願第６１／２５８，０５１号（２００９年１１月４日出願）の利益を主張し、該仮出願は各々、引用によりその全体が本明細書に組み込まれる。
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
US20140227250A1 (en) * 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
CN107428828A (zh) 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白
EA038332B1 (ru) * 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
RU2731212C2 (ru) * 2015-09-09 2020-08-31 Новартис Аг Направленная доставка высушенных распылением композиций в легкие
PT3347377T (pt) 2015-09-09 2021-04-30 Novartis Ag Anticorpos que se ligam à linfopoietina do estroma tímico (tslp) e métodos de utilização dos anticorpos
CL2016000915A1 (es) 2016-04-15 2016-11-11 Univ Pontificia Catolica Chile Uso de una composición que comprende al menos un anticuerpo monoclonal humanizado o moléculas neutralizantes que neutralizan la función de las moléculas tslp y/o tslpr y/o ox40l y/o cd177, para preparar un medicamento para el tratamiento o para aminorar los síntomas y enfermedad de pacientes infectados con el metapneumovirus humano (hmpv)
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
JP2021510723A (ja) * 2018-01-26 2021-04-30 ノバルティス アーゲー 吸入型治療薬の高用量送達

Also Published As

Publication number Publication date
JP7680654B2 (ja) 2025-05-21
IL292437A (en) 2022-06-01
ES3017790T3 (en) 2025-05-13
MY210226A (en) 2025-09-04
WO2021083908A1 (en) 2021-05-06
CO2022005391A2 (es) 2022-08-19
HRP20250300T1 (hr) 2025-04-25
ZA202205936B (en) 2025-11-26
TW202131947A (zh) 2021-09-01
MX2022005083A (es) 2022-07-19
CR20220189A (es) 2022-08-19
JP2025094236A (ja) 2025-06-24
KR20220088752A (ko) 2022-06-28
EP4534075A2 (en) 2025-04-09
HUE071069T2 (hu) 2025-07-28
CL2023003432A1 (es) 2024-05-17
US12178911B2 (en) 2024-12-31
AU2020376222A1 (en) 2022-06-02
US20250099386A1 (en) 2025-03-27
TWI891670B (zh) 2025-08-01
JP2022554249A (ja) 2022-12-28
PT4051708T (pt) 2025-04-03
EP4051708B1 (en) 2025-01-08
FI4051708T3 (fi) 2025-03-31
JP2025169423A (ja) 2025-11-12
SI4051708T1 (sl) 2025-06-30
US11904053B2 (en) 2024-02-20
UA129038C2 (uk) 2024-12-25
DK4051708T3 (da) 2025-03-24
US20230201120A1 (en) 2023-06-29
RS66646B1 (sr) 2025-04-30
CA3154999A1 (en) 2021-05-06
EP4051708A1 (en) 2022-09-07
US20210121406A1 (en) 2021-04-29
SMT202500220T1 (it) 2025-07-22
BR112022008031A2 (pt) 2022-07-12
MA57519B1 (fr) 2025-04-30
LT4051708T (lt) 2025-04-10
AR120309A1 (es) 2022-02-09
CN114867748A (zh) 2022-08-05
PH12022551022A1 (en) 2023-03-06

Similar Documents

Publication Publication Date Title
HUE071069T2 (hu) Tímusz sztrómális limfopoietint (TSLP) kötõ antitestek szárazpor készítményei és eljárások ezek alkalmazására
ZA202110236B (en) Antibody capable of binding to thymic stromal lymphopoietin and use thereof
ZA201801075B (en) Thymic stromal lymphopoietin (tslp)¿binding antibodies and methods of using the antibodies
IL257599A (en) Antibodies binding thymus thymus lymphopoietin (tslp) and methods of using the antibodies
IL280963A (en) Anti-5gdf1 antibodies, compounds and methods of use
ZA202102034B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
EP3864142A4 (en) CHEMERA ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
SI3615066T1 (sl) Formulacije človeških protiteles proti-RANKL in postopki njihove uporabe
IL290141A (en) Formulations of anti-pvrig antibodies and uses thereof
EP3893917A4 (en) IL-15 COMPOSITIONS AND METHODS OF USE THEREOF
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
SG11202108403UA (en) Anti-clec2d antibodies and methods of use thereof
SG11202103907PA (en) Formulations of anti-rsv antibodies and methods of use thereof
IL290741A (en) Antibodies against cd-96 and methods of using them
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
SG11202105010UA (en) Antibodies to mucin-16 and methods of use thereof
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
IL284208A (en) Antibody formulations that bind human cd137 and their uses
EP3914290A4 (en) ANTI-ELASTIN ANTIBODIES AND METHODS OF USE
HK40057777A (en) Formulations of anti-rsv antibodies and methods of use thereof
HK40076227A (en) Antigenic polypeptides and methods of use thereof
HK40076228A (en) Antigenic polypeptides and methods of use thereof
EP4003536A4 (en) ANTIGEN POLYPEPTIDES AND THEIR METHODS OF USE
HK40049093A (en) Antibodies to mucin-16 and methods of use thereof